Literature DB >> 30759408

Urinary metabolomics for discovering metabolic biomarkers of laryngeal cancer using UPLC-QTOF/MS.

Jian Chen1, Hongwei Hou2, Huan Chen3, Yanbo Luo3, Lirong Zhang4, Yunfei Zhang5, Hansong Liu6, Fangfang Zhang6, Yong Liu7, An Wang8, Qingyuan Hu9.   

Abstract

The incidence of laryngeal cancer (LYC) is second only to lung cancer, which is also the second most common cancer in head and neck cancer. Risk assessment metabolomics biomarkers to diagnose LYC have not been found by now. To profile the metabolites in healthy controls (HCs) and LYC patients (LYCs), urine metabonomics study was performed based on reversed phase liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (RPLC-QTOF/MS). Six urine differentially expressed metabolites (Variable Importance in Projection >1, p <  0.05) were identified by searching reference library or comparing with standard based on OPLS-DA (orthogonal partial least squares-discriminant analysis) model. d-pantothenic acid, palmitic acid, myristic acid, oleamide, sphinganine and phytosphingosine were identified as differential metabolites associated with the LYC and they might play roles in sphingolipid metabolism, fatty acid biosynthesis, fatty acid elongation in mitochondria, pantothenate and coenzyme A (CoA) biosynthesis, beta-Alanine metabolism and fatty acid metabolism. These six differential metabolites were combined to test the potentiality of diagnosis of LYC. Results revealed that the area under the curve (AUC) value, sensitivity and specificity of receiving operator characteristic (ROC) curve were 0.97, 95% and 97%, respectively, indicating that this diagnosis method could be used to distinguish LYCs from HCs with good sensitivity and specificity.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Diagnosis; Laryngeal cancer; RPLC-QTOF/MS; Urinary metabolomic

Mesh:

Substances:

Year:  2019        PMID: 30759408     DOI: 10.1016/j.jpba.2019.01.035

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Metabolomics of Oral/Head and Neck Cancer.

Authors:  Gaofei Yin; Junwei Huang; Wei Guo; Zhigang Huang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients.

Authors:  Oiana Telleria; Oihane E Alboniga; Marc Clos-Garcia; Beatriz Nafría-Jimenez; Joaquin Cubiella; Luis Bujanda; Juan Manuel Falcón-Pérez
Journal:  Metabolites       Date:  2022-06-15

3.  Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.

Authors:  Rui Wang; Huaixing Kang; Xu Zhang; Qing Nie; Hongling Wang; Chaojun Wang; Shujun Zhou
Journal:  BMC Cancer       Date:  2022-02-28       Impact factor: 4.430

4.  The Ameliorative Effects of Arctiin and Arctigenin on the Oxidative Injury of Lung Induced by Silica via TLR-4/NLRP3/TGF-β Signaling Pathway.

Authors:  Xueying Liu; Jian Wang; Peiyuan Dou; Xu Zhang; Xiaoku Ran; Linlin Liu; Deqiang Dou
Journal:  Oxid Med Cell Longev       Date:  2021-07-17       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.